Management of acute graft versus host disease (GvHD)

Hematology Journal

Volumn 5, Issue 3, 2004, Pages 189-196

  Bacigalupo, Andrea ^a   Palandri, Francesca ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Bone marrow transplantation; GvHD; Leukemia

Indexed keywords

ALENTUZUMAB; ANTINEOPLASTIC AGENT; BUSULFAN; CALCINEURIN INHIBITOR; CD147 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; FLUDARABINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD147; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; STEROID; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; CHRONIC DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; EARLY DIAGNOSIS; EXPECTATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HOST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; INFUSION; LOW DRUG DOSE; LYMPHOCYTE; LYMPHOCYTE DEPLETION; MESENCHYME CELL; MORBIDITY; MORTALITY; NEPHROTOXICITY; REVIEW; RISK REDUCTION; STEM CELL; T LYMPHOCYTE; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; STEM CELL TRANSPLANTATION;

EID: 3142665403     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200399     Document Type: Review

References (79)

1. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
2. Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877-3886.
3. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-864.
4. Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112: 219-227.
5. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
6. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
7. Martin PJ, Kernan NA. T-cell depletion for GHD prevention in humans. In: Ferrara JLM, Deeg HJ (eds) Graft-versus-Host Disease. Marcel Dekker: New york, 1997; pp. 615-637.
8. Hows J, Bradley B, Gore S, Downie T, Howard M, Gluckman E et al. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371-380.
9. Baurmann H, Bonnefoy-Bérard N, Thiede C, Oelschlägel U, Ehninger G, Revillard JP et al. Clinical and biological effects of ATG used as part of the conditioning in matched unrelated donor (MUD) transplantation. Blood 1999; 94 (Suppl 1, part 1): 134a.
10. Holler E, Ledderose G, Knabe H, Muth A, Gunther C, Wilmanns W et al. ATG serotherapy during pre-transplant conditioning in unrelated donor BMT: dose-dependent modulation of GVHD. Bone Marrow Transplant 1998; 21 (Suppl 1): 105a.
11. Byrne JL, Stainer C, Cull G, Haynes AP, Bessell EM, Hale G et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant 2000; 25: 411-417.
12. Finke J, Bertz H, Schmoor C, Veelken H, Behringer D, Wasch R et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000; 111: 303-313.
13. Zander AR, Zabelina T, Kroger N, Renges H, Kruger W, Loliger C et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999; 23: 889-893.
14. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
15. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.
16. Bacigalupo A, Lamparelli T, Gualandi F, Bregante S, Raiola AM, Di Grazia C et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood and Marrow Transplant 2002; 8: 656-661.
17. Storb R, Deeg HJ, Witehead J, Appelbaum F, Beatty P, Bensinger W et al. Marrow transplantation for leukemia: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of GVHD after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
18. Zikos P, van Lint MT, Frassoni F, Lamparelli T, Gualandi F, Occhini D et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose Cyclosporin versus low-dose Cyclosporin and low-dose Methotrexate. Blood 1998; 91: 3503-3508.
19. Bacigalupo A, van Lint MT, Occhini D, Gualandi F, Lamperelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423-1428.
20. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low dose cyclosporine reduces the risk of relapse in children with acute leukemia given HLA identical sibling bone marrow transplantation: results of a radomized trial. Blood 2000; 95: 1572-1579.
21. Bacigalupo A, Lamparelli T, Gualandi F, Bregante S, Raiola AM, Di Grazia C et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia: a 10 year follow up of a randomized study. Blood 2001; 98: 3174-3175.
22. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
23. Bornhäuser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499-504.
24. Storb R, Yu C, Sanmeier BM, Mc Sweeney PA, Georges G, Nash RA et al. Mixed hemopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Ann NY Acad Sci 1999; 872: 372-375.
25. Basara N, Blau WI, Kiehl MG, Schmetzer B, Bischoff M, Kirsten D et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant 2000; 14: 121-126.
26. Pittenger MF, MacKay AM, Beek C. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-145.
27. Klyushnenkova EN, Mosca J, McIntosh KR. Human mesenchymal stem cells suppress allogeneic T cell responses in vitro: implications for allogeneic transplantation. Blood 1998; 92: 642a.
28. Tse WT, Beyer W, Pendleton JD, D'Andrea A, Guinan EC. Bone marrow derived mesenchymal stem cells suppress T cell activation without inducing allogeneic anergy. Blood 2000; 96: 1034a.
29. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntoch K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48.
30. Nagwa S, El-Badri, Wang Bin Yang, Good RA. Osteoblast promote engraftment of allogeneic hematopoietic stem cells. Exp Hematol 1998; 26: 110-114.
31. Lazarus H, Curtin P, Devine S, McCarthy P, Holland K, Moseley A et al. Role of mesenchymal stem cells (MSC) in allogeneic transplantation: early phase I clinical results. Blood 2000; 96: (abst. 1691) p. 392a.
32. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of hos antigen-presenting cells. Science 1999; 285: 412-415.
33. Ordemann R, Hutchinson R, Friedman J, Burakoff SJ, Reddy P, Duffner U et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest 2002; 109: 1249-1256.
34. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Med 2002; 8: 575-581.
35. Chan G, Foss FM, Roberts T, Sprague K, Schenkein D, Miller KB. Decreased acute and chronic graft versus host disease with early full donor engraftment following a pentostatin-based preoperative regimen for allogeneic bone marrow transplant in high-risk patients. Blood 2001; 98: (abstr 1612) 383a.
36. Gorgun G, Alcindor T, Rao R, Foss F. Immunologic mechanism of extracorporeal photochemotherapy (ECP) in chronic GVHD. Blood 2001; 98: (abstr 2729) 650a.
37. Ruggeri L, Shlomchik WD, Capanni M, Perruccio K, Velardi A. Donor-versus-recipient alloreactive NK cells prevent gVHD by killing host APC in MHC disparate hematopoietic transplants. Blood 2001; 98: (abstr. 3378) 813a.
38. Hobbs JR, Barrett AJ, Chambers D, James DCO, Hugh-Jones K, Byrom N et al. Reversal of clinical features of hurler's disease and biochemical improvement after treatment by bone marrow transplantation. Lancet 1981; 3: 709-712.
39. Storb R, Erzioni R, Anasetti C, Appelbaum FR, Buckner CD, Besinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
40. Sociè G, Lawler M, Gluckman E, McCann S, Brison O. Studies on hemopoietic chimerism following allogeneic bone marrow transplantation in the molecular biology era. Leuk Res 1995; 19: 497-504.
41. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Byers V et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
42. Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Mordini N, Berisso G et al. Reduced intensity thiothepa-cyclophosphamide conditioning for allogeneic hemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 2000; 109: 716-721.
43. Kottaridis PD, Chakraverty R, Milligan DW, Chakrabarti S, Robinson S, Chopra R et al. A non-myeloablative regimen for allogeneic stem cell transplantation with a low incidence of GVHD. Bone Marrow Transplant 2000; 25: S26.
44. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, Obrien S et al. Transplant lite: induction of graft versus malignancy using fludarabine based non ablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignances. J Clin Oncol 1998; 16: 2817-2824.
45. Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 2002; 29: 191-195.
46. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin- 2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 345: 1144-1146.
47. Anasetti C, Lin A, Nademanee A, Gluckman E, Messner H, Beatty P et al. A phase II/III randomized double blind, placebo-controlled multicentre trial of humanised anti-Tac for prevention of acute graft-versus-host disease in recipients of marrow transplantats from unrelated donors. Blood 1995; 86 (Suppl 1): 621a.
48. Hoeller E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell Th et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNF α) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF α (MAK 195F). Biol Blood Marrow Transplant 2002; 8: 1-8.
49. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-1472.
50. van Lint MT, Uderzo C, Locasciulli A, Maiolino L, Scimé R, Locatelli F et al. Early treatment of a GvHD with high or low dose of 6Mpred: a multicenter randomised trial for Bone Marrow Transplantation for the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288-2293.
51. Hsu B, May R, Carrum G, Krance R, Przepiorka D. The criteria for steroid-refractory acute graft-versus host disease: an international practice survey. Blood 2001; 98: (abstr. 2779) 663a.
52. Roy J, McGlave PB, Filipovich AH, Miller WJ, Blazar BR, Ramsay NK et al. Acute graft versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992; 10: 77-82.
53. Aschan J. Treatment of moderate to severe acute GvHD: a retrospective analysis. Bone Marrow Transplant 1994; 14: 601-607.
54. Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 441-447.
55. MacMillan ML, Weisdorf DJ, Davies SM, De For TE, Burns LJ, Ramsay NKC et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 40-46.
56. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360-2368.
57. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation 1998; 65: 1481-1489.
58. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001; 98: 2052-2058.
59. Bacigalupo A, Oneto R, Bruno B, Soracco M, Lamparelli T, Gualandi F et al. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transplantation 1999; 24: 653-659.
60. Bacigalupo A, Oneto R, Lamparelli T, Gualandi F, Bregante S, Raiola AM et al. Pre-emptive therapy of acute graft versus host disease: a pilot study with anti-thymocyte globulin (ATG). Bone Marrow Transplant 2001; 28: 1093-1096.
61. Ramsay NKC, Kersey JH, Robinson LL, McGlave PB, Woods WG, Krivit W et al. A randomized study of the prevention of acute graft versus host disease. N Engl J Med 1982; 306: 392-397.
62. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
63. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibitis murine graft-versus-host disease. Blood 1995; 86: 2429-2438.
64. Sykes M, Pearson DA, Taylor PA, Szot GL, Goldman SJ, Blazar BR. Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-versus-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. Biol Blood Marrow Transplant 1999; 5: 277-284.
65. Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA et al. Differential effects of the absence of interferon-γ and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998; 102: 1742-1748.
66. Minasi LE, Kamogawa Y, Carding S, Bottomly K, Flavell RA. The selective ablation of interleukin 2 producing cells isolated from transgenic mice. J Exp Med 1993; 177: 1451-1459.
67. Kamogawa Y, Minasi LE, Carding SR, Bottomly K, Flavell RA. The relationship of IL-4 and IFN-producing T cells studies by lineage ablation of IL-4 producing cells. Cell 1993; 75: 985-995.
68. Nakamura T, Kamogawa Y, Bottomly K, Flavell RA. Polarization of IL-4 and IFN-gamma-producing CD4+ T cells following activation of naive CD4+ T cells. J Immunol 1997; 158: 1085-1094.
69. Liu J, Anderson BE, Robert ME, McNiff JM, Emerson SG, Shlomchik WD et al. Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease. Blood 2001; 98: 3367-3375.
70. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476.
71. Ljungman P. Prevention and treatment of viral infections in stem cell transplant recipients. Br J Haematol 2002; 118: 44-57.
72. Van Esser JW, van der Holt B, Meijer E, NiestersHG, Trenschel R, Thijsen SF et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and qualitatively predicts EBV-lymphoproliferative disease following T cell depleted SCT. Blood 2001; 98: 972-978.
73. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A., For the European Group for Blood and Marrow Transplantation. Transplantation of mobilized peripheral blood cells to HLA identical siblings with standard risk leukaemia. Blood 2002; 100: 761-767.
74. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
75. Couban S, Simpson R, Barnett MJ, Bredeson C. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1528.
76. Blaise D, Kuentz M, Container C. Randomized trial of bone marrow versus lenograstim primed blood cell allogeneic transplantation. J Clin Oncol 2000; 18: 537-546.
77. Rocha V, Wagner Jr JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342: 1846-1854.
78. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C et al. Comparison of outcomes of unrelated bone marrow and umbelical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-2971.
79. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1860-1861.